

Marc Recht

Partner



mrecht@cooley.com

+1 617 937 2316

Boston

Public Companies
Capital Markets
Life Sciences
Mergers and Acquisitions
Emerging Companies
Medtech
Digital Health
Venture Capital
Biotechnology
CooleyREG

Marc is co-chair of Cooley's global life sciences industry practice. For over 20 years, he has represented life sciences and other healthcare companies and investors in public and private transactions, including securities offerings, joint ventures and M&A matters. He also has extensive experience advising public companies boards of directors and management teams regarding Securities and Exchange Commission periodic disclosure, Sarbanes-Oxley compliance, corporate governance and Nasdaq and New York Stock Exchange rules.

Some of Marc's recent transactions include:

Capital markets:

- Morgan Stanley (lead underwriter): \$150 million (common stock) Talaris Therapeutics IPO
- Valneva: \$170.6 million (ADS and ordinary shares) US IPO and European private offering
- Keros Therapeutics: \$110.4 million (common stock) IPO
- Morgan Stanley (lead underwriter): \$75.2 million (common stock) Imara Inc. IPO
- DBV Technologies: \$143 million (ADS) follow-on offering
- Jefferies (lead underwriter): \$103.5 million (common stock) Morphic Therapeutic IPO
- Prevail Therapeutics: \$125 million (common stock) IPO
- Milestone Pharmaceuticals: \$94.9 million (common stock) initial public offering
- DBV Technologies: \$81 million (ADS) follow-on offering
- Genfit: \$155.4 million (ordinary shares) IPO
- Avedro: \$70 million (common stock) IPO
- Stifel Nicolaus (lead underwriter): \$33.3 million (common stock) Selecta Biosciences follow-on offering
- Jefferies (lead underwriter): \$86 million (common stock) Scholar Rock IPO
- Wells Fargo (lead underwriter): \$54 million (ADS) Celyad S.A. follow-on offering
- DBV Technologies: \$173 million (ADS) follow-on offering
- Cantor Fitzgerald (lead underwriter): \$55 million (common stock and warrants) Genocea Biosciences follow-on offering

- Stifel Nicolaus (lead underwriter): \$33.3 million (common stock) Selecta Biosciences follow-on offering
- ERYTECH Pharma (France): \$144 million IPO
- Nightstar Therapeutics plc (UK): \$86 million IPO
- UBS Securities (lead underwriter): \$80 million Selecta Biosciences IPO
- Citigroup (lead underwriter): \$55 million Merus IPO
- Cowen & Co. (lead underwriter): \$86 million Voyager Therapeutics IPO
- Immunocore (UK): \$320 million (ordinary shares) cross-over financing
- UBS Securities (lead underwriter): \$100.1 million Celyad IPO
- DBV Technologies: \$282 million (common stock) follow-on offering
- Cowen & Co. (lead underwriter): \$52 million (common stock) Genocea Biosciences follow-on offering
- Flex Pharma: \$99.4 million (common stock) IPO
- Citigroup (lead underwriter): \$133 million (representing ADRs and ordinary shares) DBV Technologies IPO and global private offering
- Jefferies (lead underwriter): \$60 million (common stock) Regado Biosciences follow-on offering
- Eagle Pharmaceuticals: \$50 million (common stock) IPO
- Flexion Therapeutics: \$65 million (common stock) IPO
- Citigroup (lead underwriter): \$66 million (common stock) Genocea Biosciences IPO

M&A and licensing/collaborations:

- Avedro sale to Glaukos
- Regado Biosciences merger with Tobira Therapeutics
- Biondi merger with Albireo
- Eagle Pharmaceuticals' license agreement with Cephalon (a subsidiary of Teva) for Eagle's formulation of bendamustine
- Ziopharm license agreement with Intrexon and MD Anderson Cancer Center for the acquisition of certain CAR-T assets and programs
- Forma Therapeutics Holdings' \$600 million exclusive collaboration and option with Celgene
- Forma Therapeutics Holdings' \$945 million multiprogram collaboration and option with Celgene
- Objet (Israel) merger with Stratasys (US), valued at \$1.4 billion
- Clinical Data: Acquired by Forest Laboratories for \$1.6 billion in cash
- Astex Therapeutics: Acquired by SuperGen for \$60 million in cash and stock

Prior to joining the firm, Marc was a corporate partner in the Boston office of a major international law firm.

Marc has been recognized by Chambers USA in the Massachusetts Capital Markets category since 2014. He has also been recognized for his work in Life Sciences and Healthcare by the Legal 500 in its 2013, 2016 and 2020 US editions. Who's Who Legal named Marc a leading life sciences lawyer in its 2017 and 2018 editions.

While at Boston College Law School, Marc was the articles editor of the Third World Law Journal.

Education

Boston College Law School

JD, 1999

Brandeis University

BA, 1995

Admissions & Credentials

Massachusetts

Rankings & Accolades

Chambers USA: Capital Markets – Massachusetts (2014 – 2024)

The Legal 500 US: Healthcare: Life Sciences (2013, 2016, 2020)

Who's Who Legal: Life Sciences (2017, 2018)

Super Lawyers: Rising Star (2007, 2010 – 2013)

Boston Business Journal: Biotech IPO (2015)